Important piece of information about the safety profile of Enza+Talazoparib in TALAPRO-2 trial. No  significant differences in HRR-deficient and all-comers. Special attention to G3-4 anemia (40-46%) and G3-4 neutropenia (18%). www.ejcancer.com/article/S095...